Ratings GlaxoSmithKline Pharmaceuticals Limited NSE India S.E.

Equities

GLAXO

INE159A01016

Market Closed - NSE India S.E. Other stock markets 12:43:48 03/05/2024 BST			5-day change	1st Jan Change
2,095 ^INR	-0.30%		-1.56%	+10.39%

04-25	GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology	RE
03-22	GlaxoSmithKline Pharmaceuticals Limited Receives Orders from Government Authorities	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52.09 times its estimated earnings per share for the ongoing year.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED	+10.39%	4.25B	-
NOVO NORDISK A/S	+21.85%	546B	B
JOHNSON & JOHNSON	-4.77%	359B	C+
MERCK & CO., INC.	+16.97%	323B	B-
ABBVIE INC.	+5.69%	290B	C+
ASTRAZENECA PLC	+13.68%	234B	B+
NOVARTIS AG	+3.65%	198B	B-
ROCHE HOLDING AG	-11.12%	194B	A+
AMGEN INC.	+8.08%	167B	C+
PFIZER, INC.	-3.40%	157B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes